Camptodactyly arthropathy coxa vara pericarditis syndrome

From WikiMD's WELLNESSPEDIA

Alternate names[edit]

Arthropathy camptodactyly syndrome; Pericarditis arthropathy camptodactyly syndrome; PAC syndrome; Fibrosing serositis, familial; Camptodactyly arthropathy pericarditis syndrome; Congenital familial hypertrophic synovitis; Camptodactyly-arthropathy-coxa vara-pericarditis syndrome; Arthropathy-camptodactyly syndrome; CACP syndrome; Camptodactyly-arthropathy-coxa-vara-pericarditis syndrome; Jacobs syndrome; Pericarditis-arthropathy-camptodactyly syndrome

Definition[edit]

Camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) is a rare condition which causes joint abnormalities that begin at birth or during early childhood. The name comes from the main symptoms, including permanent bending of the fingers (camptodactyly), joint disease (arthropathy), and changes in the hip joint resulting in shortened legs and a possible limp (coxa vara).

Cause[edit]

  • Camptodactyly-arthropathy-coxa-pericarditis syndrome is caused by a change (mutation) in the PRG4 gene.
  • This gene provides the instructions for making lubricin, a protein (part of synovial fluid) that lubricates the joints.
  • In other words, lubricin works like oil in a hinge and is needed so the joints can bend easily without a lot of force or causing damage to the bones. Lubricin also works as an lubricant between the two layers of the thin sac which surrounds the heart (pericardium).
  • The pericardium holds the heart in place and helps it work properly.
  • In addition lubricin keeps the thin coverings of tendons (tendon sheaths) from sticking to the thin fibrous coverings (sheaths) of muscles and organs as well as controls cell growth of special cells (synovial fibroblasts) which are part of the thin covering (synovial membrane) surrounding the synovial fluid within joints.

Inheritance[edit]

Autosomal recessive inheritance, a 25% chance

The condition is inherited in an autosomal recessive manner. This means that to be affected, a person must have a mutation in both copies of the PRG4 gene in each cell. People with CACP inherit one mutated copy of the gene from each parent, who is referred to as a carrier. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When two carriers of an autosomal recessive condition have children, each child has a:

  • 25% chance to be affected (have CACP)
  • 50% chance to be an unaffected carrier like each parent
  • 25% chance to be unaffected and not a carrier

Signs and symptoms[edit]

  • It is a rare condition which causes joint abnormalities that begin at birth or during early childhood.
  • The name comes from the main symptoms, including permanent bending of the fingers (camptodactyly), joint disease (arthropathy), and changes in the hip joint resulting in shortened legs and a possible limp (coxa vara).
  • Some people with CACP also have too many cells between their joints (synovial hyperplasia) and too much fluid around the heart (pericardial effusion) or lungs (pleural effusion).

Diagnosis[edit]

Treatment[edit]

  • At present there is no cure or specific treatment for camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP).
  • Treatment options such as physical therapy and pain medication focus on relieving the symptoms of the disease.
  • Hip joint replacement surgery may also be an option.
  • The medication for juvenile idiopathic arthritis is not helpful for those with CACP.

NIH genetic and rare disease info[edit]

Camptodactyly arthropathy coxa vara pericarditis syndrome is a rare disease.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.